Stock Spotlight

Drugmaker Mylan far from generic

Recent Price
$54
Dividend (estimated)
$0.00
Yield (estimated)
0.0%
P/E Ratio
16
Shares (millions)
397
Long-Term Debt as % of Capital
63%
52-Week Price Range
$59.60 - $41.41

We dropped generic-drug maker Mylan ($54; MYL) from the Focus, Buy, and Long-Term Buy lists last December because of eroding Quadrix scores and softening revenue growth. Both have since recovered.

The Overall score is up to 92 from 45 at the end of September. Sales growth has accelerated in the past few quarters, helped by product launches and the $1.4 billion acquisition of Agila Specialties in December 2013. Mylan is also benefiting from the confluence of rising utilization and high prices for many generic drugs.

In July, Mylan agreed to pay nearly $6 billion in stock for Abbott Laboratories' ($44; ABT) specialty and generic business in developed countries outside of the U.S. The deal, expected to close in the March quarter, should boost Mylan's annual sales by $2 billion. Although U.S. lawmakers have introduced new rules to make tax inversions more difficult for U.S. companies, Mylan is moving forward with plans to use the transaction to reincorporate itself in the Netherlands.

Mylan has a strong track record for growing cash flow. Cash from operations, up more than 15% in five of the past six calendar years, is up 29% for the first nine months of 2014. Free cash flow has surged 48% this year. The stock, already a Long-Term Buy, was added to the Buy List in the December 8 issue.

Business breakdown

Mylan relied on generic drugs for 83% of sales in the first nine months of 2014, with the remainder coming from its more profitable specialty-drug unit. A steady stream of new-product launches is crucial for Mylan, because competition can quickly erode sales and profit margins of generic drugs.

The company currently has 44 first-to-file Abbreviated New Drug Applications with U.S. regulators. Pending approval, Mylan will get 180 days of exclusive rights to sell these drugs before other generic manufacturers can enter the market. The 44 branded drugs in question have annual sales totaling $29.5 billion.

Gilead Sciences ($101; GILD) has approved Mylan to sell a generic form of hepatitis C drug Sovaldi in developing markets, as well as to sell its HIV drug in 112 countries that account for 84% of the world's HIV cases.

Mylan's pricing power could face some resistance in the U.S. In late November, U.S. senators began to investigate the surge in generic-drug prices after a study found that half of them rose in the past year, some by as much as 500%. North America accounts for 51% of Mylan's generic-drug sales.

Analysts' 2015 profit estimates for the broad S&P 500 health-care sector have declined in recent weeks. But revision trends are positive for both the pharmaceuticals industry and Mylan. The consensus expects Mylan to grow earnings per share 16% in 2015.

Mylan earns a middling Value rank of 51. But the shares look attractive relative to peers and their own history. At 18 times trailing earnings, the stock trades 6% below its five-year average and 16% below the median for S&P 500 drugmakers. Mylan shares also trade 17% below their peer-group median relative to estimated 2015 earnings.

An annual report for Mylan Inc. is available at 1000 Mylan Blvd., Canonsburg, PA 15317; (724) 514-1800; www.mylan.com.


 

Mylan

 
Quarter
Per-Share Earnings
Sales Change
Quarterly Price Range
P/E Ratio Range
Sep '14
$1.16
vs.
$0.82
18%
$53.05
-
$44.80
18 - 15
Jun '14
0.69
vs.
0.68
8%
55.30
-
44.74
19 - 15
Mar '14
0.66
vs.
0.62
5%
57.52
-
41.97
20 - 14
Dec '13
0.78
vs.
0.65
5%
44.73
-
36.97
16 - 13

 
Year (Dec.)
Sales (Bil.)
Per-Share Earnings*
Per-Share Dividend
52-Week Price Range
P/E Ratio Range
2013
$6.91
$2.89
$0.00
$44.73
-
$27.38
15 - 9
2012
6.80
2.59
0.00
28.50
-
20.21
11 - 8
2011
6.13
2.04
0.00
25.46
-
15.49
12 - 8
2010
5.45
1.61
0.00
23.63
-
16.55
15 - 10

 
Quadrix Scores†
Overall
Momentum
Value
Quality
Financial Strength
Earnings Estimates
Performance
92
89
51
90
52
95
81

* Earnings exclude special items. NM Not Meaningful.
† Quadrix® scores are percentile ranks, with 100 the best.
e Dividend and yield estimated.

More Investment Newsletters and Services

Drip Investor

DRIP Investor — how you can buy dividend-paying stocks without a broker.

Visit us at DRIP Investor, your source for dividend reinvestment plans.

Lazy Investor

The Lazy Investor — free weekly e-letter that delivers market updates and stock market information via email.

Visit us at The Lazy Investor, our free investment newsletter.

Horizon Investment

Horizon — registered investment advisor seeks to provide investors at all stages the ability to build, preserve and enjoy wealth.

Visit us at Horizon Investment Services to get started in an investment program that's right for you.

Upside

Upside — discovers today's small and midcap stocks poised to be tomorrow's Blue Chip leaders.

Visit us at Upside, your guide to the best buys in small and midcap stocks.

Current Hotline

Friday, December 19, 2014

It took seven trading days for the Dow Industrials to fall 5% from their all-time high of 17,958.79 reached Dec. 5

Read More from the Hotline

Stock Spotlight

Drugmaker Mylan far from generic

Wednesday, December 17, 2014

We dropped generic-drug maker Mylan ($54; MYL) from the Focus, Buy, and Long-Term Buy lists last December because of eroding Quadrix scores and softening revenue...

Read More from Stock Spotlight

Individual Stock Reports

ISRs make stock research easy!

Perhaps the most valuable two page reports available anywhere.

All the data you would normally have to plow through years of 10-K filings, earnings reports, and reams of market data to assemble — yours all in one concise report.

ISRs contain our proprietary Quadrix scores — find out how we rate all the stocks in the S&P 500.

Visit us at individualstockreports.com